| 产品名称 | SKI 606 - Bosutinib |
| 产品货号 | Axon 1407 CAS [380843-75-4] MF C26H29Cl2N5O3MW 530.45 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description A tyrosine kinase inhibitor (TKI), targeting dual Bcr-Abl and Src; effective drug for chronic myelogenous leukemia (CML) or acute lymphoid leukemia (ALL) References Certificates Categories Extra info A Vultur et al. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol. Cancer Ther. 2008, 7(5), 1185–1194. W. A. Messersmith et al.Bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor: Preliminary results from a phase 1 study in patients with advanced malignant solid tumors. J. Clinical Oncol. 2007, 25 (18S), 3552. JM Goldman, JV Melo. BCR-ABL in Chronic Myelogenous Leukemia - How Does It Work? Acta Haematol. 2008, 119, 212-217. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology BCR-ABL SRC Oncogene Fusion Proteins EC 2.7.10.1 Pfizer Licensed Products Bcr-Abl and Src tyrosine kinase inhibitor Chemical name 4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrile Source information Pfizer compound; Sold for research purposes under agreement from Pfizer Inc. Parent CAS No. [380843-75-4] Order Size Unit Price Stock 5 mg €75.00 In Stock |
| 产品价格 | 现货询价，电话：010-67529703 |
| 产品规格 | |
| 产品品牌 | axonmedchem |
| 产品概述 | |
| 产品详情 |
SKI 606 - BosutinibAxon 1407 CAS [380843-75-4] MF C26H29Cl2N5O3
Description
A tyrosine kinase inhibitor (TKI), targeting dual Bcr-Abl and Src; effective drug for chronic myelogenous leukemia (CML) or acute lymphoid leukemia (ALL)
Bcr-Abl and Src tyrosine kinase inhibitor
Chemical name4-(2,4-Dichloro-5-methoxy-phenylamino)-6-methoxy-7-[3-(4-methyl-piperazin-1-yl)propoxy]quinoline-3-carbonitrile Source informationPfizer compound; Sold for research purposes under agreement from Pfizer Inc.Parent CAS No.[380843-75-4] |
| 产品资料 |
